Pharmaceutical Giants Unite to Boost AI-Driven Drug Discovery

Pharmaceutical Collaboration for AI-Driven Drug Discovery

In a groundbreaking move, major pharmaceutical companies are joining forces to accelerate drug discovery and development through artificial intelligence. Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals have announced their participation in a consortium that includes industry giants AbbVie and Johnson & Johnson1

1

. This collaborative effort aims to harness the power of AI to revolutionize the drug discovery process.

The OpenFold3 AI Model

The centerpiece of this initiative is an AI model called OpenFold3, which will be trained on a vast array of proprietary data contributed by the participating companies. Specifically, the consortium members will share data from several thousand experimentally determined protein-small molecule structures2

2

. By pooling these extensive datasets, the initiative seeks to enhance OpenFold3's accuracy in predicting interactions between proteins and small molecules, a crucial aspect of drug discovery.

Federated Data Sharing: Balancing Collaboration and Security

A key feature of this collaboration is the use of a federated data sharing model. This innovative approach allows companies to work together without exposing sensitive proprietary information. Germany-based life sciences company Apheris provides the computing platform that enables this secure collaboration1

1

.

Payal Sheth, Vice President of Discovery Biotherapeutics and Lead Discovery and Optimization at Bristol Myers Squibb, highlighted the significance of this approach: "The federated platform allows multiple companies to advance predictive models for small molecule discovery in ways no single organization could achieve alone"2

2

.

Industry-Wide AI Integration

This consortium is part of a broader trend in the pharmaceutical industry to integrate AI across all aspects of drug development. Hans Bitter, Head of Computational Sciences at Takeda, emphasized this point, stating, "This consortium really ties into our larger corporate goal of embedding AI throughout all of what we do"1

1

.

Collaboration for Patient Benefit

The initiative not only showcases the potential of AI in drug discovery but also highlights the power of collaboration in the pharmaceutical industry. Bitter noted that this partnership is "a nice example of how we can come together as pharma companies and do even more for patients than we could if we did it on our own"2

2

.

The AI Structural Biology Network

OpenFold3 is the flagship project of the industry-led AI Structural Biology Network. This network is conducting its research in collaboration with the AlQuraishi Lab at Columbia University, further emphasizing the intersection of industry and academic expertise in this cutting-edge field1

1

.